vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
November 13 2017 - 7:30AM
Business Wire
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that
the Company will host a key opinion leader (KOL) presentation and
webcast focused on the current state of clinical development in
Alzheimer’s disease in New York City on Thursday, November 16, 2017
from 8:00 am to 10:00 am ET.
The event will feature two speakers, each with extensive
experience in the clinical development in Alzheimer’s:
- Dr. Howard Fillit, founding executive
director and chief scientific officer of Alzheimer’s Drug Discovery
Foundation, clinical professor of geriatric medicine, palliative
care, and neuroscience at Mt. Sinai School of Medicine
- Dr. Mary Sano, associate dean for
clinical research, professor of Psychiatry, founding member and
director of the Alzheimer’s Disease Research Center at Mt. Sinai
School of Medicine
In addition to the presentations, vTv Therapeutics will provide
a brief overview of the company's ongoing Phase 3 clinical
development program for azeliragon, an orally bioavailable small
molecule RAGE antagonist for patients with mild Alzheimer’s
disease.
To register to attend the event, contact Mike Biega, Trout
Group: mbiega@troutgroup.com or register here. Advanced
registration is required, as space is limited.
A live webcast of the event will be available on the Investor
page of vTv’s website at www.vtvtherapeutics.com. The archived
version of the webcast will be available for replay on the Events
& Presentations section of the Investors page of vTv
Therapeutics’ website for 90 days following the event.
About Azeliragon
vTv discovered and developed azeliragon using its proprietary
drug discovery platform TTP Translational Technology®. A broad
range of human pathologic and experimental biologic investigation
suggests that RAGE activation contributes to the pathogenesis of
Alzheimer’s disease. Sustained Amyloid-β interactions with RAGE at
the blood-brain barrier (BBB) and in neuronal and microglial cells,
play potentially major roles in amyloid plaque formation,
neuroinflammation and chronic neural dysfunction – all hallmarks of
Alzheimer’s disease. Azeliragon, also known as TTP488, is a novel
orally active small-molecule antagonist of RAGE.
About STEADFAST
STEADFAST, two identical randomized, double-blind,
placebo-controlled Phase 3 trials, is investigating the safety and
efficacy of azeliragon as a potential treatment to slow the decline
in cognition and functional activities for patients with mild
Alzheimer’s disease. The 18-month trial targeted enrollment of 800
patients (400 each for Part A and B). Part A enrolled patients in
the United States and Canada. Enrollment of Part B additionally
included study sites in the United Kingdom, Ireland, Australia, New
Zealand and South Africa. Subjects completing the STEADFAST study
are eligible to enroll in a 24-month open-label extension trial.
STEADFAST is being conducted following agreement with FDA under the
Special Protocol Assessment (SPA) process and the azeliragon
development program has been granted fast track designation.
Enrollment of Part A was completed in September 2016 with data
expected to read out in early 2018. Part B data is expected to read
out in late 2018.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171113005414/en/
Investors:vTv Therapeutics Inc.Mike Biega,
617-221-9660IR@vtvtherapeutics.comMedia:Pure CommunicationsKatie
Engleman, 910-509-3977Katie@purecommunications.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024